Moderna (MRNA) beats 1Q26 revenue on international COVID sales, cuts costs, and eyes mRNA-1010 flu PDUFA Aug 5.

Moderna saw its first-quarter revenues nearly triple to $389 million compared to the same period of 2025, with international ...

Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its ...

Moderna (MRNA) shares surge 8% after Q1 revenue hits $389M, tripling year-over-year and beating estimates on strong ...

This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s ...

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9 ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna said the FDA's refusal was inconsistent with previous feedback from the agency. - Graham Hughes/Bloomberg/Getty Images The ...

The people who research, make and invest in vaccines are nervous. Some companies have started pulling back on their vaccine ...

The Department of Health and Human Services had canceled hundreds of millions of dollars in funding previously committed help ...

Now, it’s worth noting Stock Advisor’s total average return is 986 % — a market-crushing outperformance compared to 199% for ...